Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-08-20
2002-02-19
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06348490
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to pharmaceutical formulations of thioctic acid and the enantiomers thereof. Formulations according to the invention are used for the production of pharmaceutical dosage forms which release the active ingredient more rapidly and have greater bioavailability than previous dosage forms.
2. Description of the Related Art
Thioctic acid (&agr;-lipoic acid) is chemically 1,2-dithia-cyclopentane-3- valeric acid. The production of free R-thioctic acid is described, for example, in DE-OS 41 37 773.
Thioctic acid is a component of cell metabolism and is thus found in many plants and animals. It acts as one of the coenzymes during oxidative decarboxylation of pyruvate and other &agr;-keto acids. Thioctic acid has been used for some time in various conditions, for example, inter alia, in liver conditions, in liver damage due to fungal poisoning and in diabetic and alcoholic polyneuropathy, a degeneration of the peripheral nerves which accompanies metabolic disorders.
The present invention relates to pharmaceutical formulations containing thioctic acid or solid salts of thioctic acid with improved bioavailability.
This invention relates not only to the racemic form, but also to the pure (R)- or (S)-thioctic acid as well as to mixtures of (R)- and (S)-thioctic acid of any desired composition. Of the pure optical isomers of thioctic acid (R- and S-form, i.e. R-thioctic acid and S-thioctic acid), unlike the racemate, the R-enantiomer has a predominantly anti-inflammatory action and the S-enantiomer has a predominantly anti-nociceptive action, wherein the anti-inflammatory action of the R-enantiomer is, for example, stronger than that of the racemate by a factor of 10.
The anti-nociceptive (analgesic) action of the S-enantiomer is, for example, stronger than that of the racemate by a factor of 6.
Thus, in comparison with the racemate, the enantiomers are much more specific and effective active ingredients.
The actions are described in EP 427 246 and EP 427 247 and in GbM 90 17 987.0 and EP 530 446.
A combination of thioctic acid with vitamins is described in EP 572 922.
R,S-Thioctic acid has a melting point of 60.5° C. R-Thioctic acid has a melting point of 50.6-50.7° C. Both are soluble at 25° C. in water at a rate of 12.14 mg/10 ml and in methanol, ethanol, chloroform, dimethylformamide and n-octanol at a rate of above 1000 mg/10 ml.
In comparison with parenteral dosage forms, orally administrable pharmaceutical preparations have a price advantage, which has a favorable effect on daily therapeutic costs. However, previous dosage forms of thioctic acid have the disadvantage of having relatively low bioavailability. Low bioavailability means that, on oral administration of the dosage form, in comparison with intravenous administration, relatively little of the unaltered active ingredient is found in the blood of the test subject or patient. As a consequence, oral administration of the medication cannot be as effective as intravenous administration of the active ingredient. There is thus an object of developing dosage forms which, together with good storage stability, have the greatest possible bioavailability.
SUMMARY OF THE INVENTION
The present invention provides dosage forms of thioctic acid and solid salts thereof having increased bioavailability in comparison with previous dosage forms. The increased bioavailability is surprisingly achieved by preparing the active ingredient in a form resistant to gastric juice, which, once it has passed into the duodenum, rapidly dissolves at the pH value of the intestinal juice. The pH value of the intestinal juice is 6.8 to 7.3. The active ingredient which may be used here is either the free thioctic acid or—more advantageously—a salt of thioctic acid.
The poor release of the active ingredient R-thioctic acid from the dosage forms prepared therefrom is disadvantageous. On release testing according to the
Deutsches Arzneibuch
[German pharmacopoeia], 10th edition (paddle agitator method) or USP XXII [United States pharmacopeia, 22nd Edition] with apparatus 2), release of the active ingredient from tablets according to Example 2a, using 0.06 N HCl as release medium at 37° C., is as follows:
after 15 minutes: 6%
after 30 minutes: 9%
disintegration time: <2 min.
This is in contrast with the behaviour of tablets prepared from the racemate of thioctic acid, which, with the same composition of the tablets, exhibit the following active ingredient release (method as above):
after 15 minutes: 99%
after 30 minutes: 100%
disintegration time: 2.5 min.
It was surprisingly found that when solid salts of R-thioctic acid were used to produce the tablets according to Example 3, good release values were again obtained (method as above):
after 15 minutes: 75%
after 30 minutes: 88%
disintegration time: <1 min.
Salt formers which may, for example, be considered are conventional bases or cations which are physiologically compatible in salt form. Examples of such substances are:
alkali or alkaline earth metals, such as sodium, potassium, calcium, magnesium;
ammonium hydroxide;
basic amino acids, such as, for example, ornithine, cystine, methionine, arginine and lysine;
amines of the formula N R1 R2 R3, in which the residues R1, R2 and R3 are identical or different and mean hydrogen, C
1
-C
4
alkyl, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, or C
1
-C
4
oxyalkyl, such as, for example, mono- and diethanolamine, 1-amino-2-propanol, 3-amino-1-propanol;
alkylenediamines with an alkylene chain of 2 to 6 C atoms, such as, for example, ethylenediamine or hexamethylene-tetramine; and
saturated cyclic amino compounds with 4 to 6 ring carbon atoms, such as, for example, piperidine, piperazine, pyrrolidone, morpholine; N-methylglucamine, creatine and tromethamine.
The salt formers have already been mentioned in the above-stated patents in general terms, but production of the salts and the particular suitability thereof for the production of certain dosage forms is not discussed. Liquid dosage forms with the tromethamine, lysine and ethylenediamine salt of R-thioctic acid are described in various patent applications, for example in EP 427 246, EP 427 247, EP 530 446.
However, these are without exception solutions in which the salt is formed in solution by combining R-thioctic acid and the appropriate base. The salt itself is not isolated and is thus not in crystalline form. Furthermore, the base is generally used in excess, such that it would not be possible to isolate a pure salt.
Salts of R-thioctic acid with L-lysine and L-arginine are mentioned in Spanish patent 313 056. However, there is no information relating to the production and characterisation of the salts nor any mention of better release and bioavailability of the active ingredient from the dosage forms produced therefrom.
Dosage forms of the racemic thioctic acid with improved bioavailability may also be achieved by their containing the solid salts of thioctic acid instead of the previously used free acid. Here too, bioavailability is surprisingly increased in comparison with the dosage form with the free thioctic acid. The above-stated salt formers may be used as the salt former in this case too. Dosage forms with these solid salts for oral administration are novel and have not hitherto been described. While the salt formers have indeed already been mentioned in general terms in various patents, there has been no discussion of their particular suitability for the production of certain dosage forms.
The present invention also provides all dosage forms containing solid salts of R-thioctic acid which are distinguished by better active ingredient release and better bioavailability than dosage forms prepared from R-thioctic acid. In contrast with the dosage forms prepared from free R-thioctic acid, the dosage forms prepared from salts of R-thioctic acid have not only the advantage of better release and bioavailability of the active ingredient, but are moreover more easily produced:
Hettche Helmut
Rischer Matthias
Sarlikiotis Werner
Asta Medica Aktiengesellschaft
Henley III Raymond
Hobbs Ann S.
Venable
LandOfFree
Dosage forms containing thioctic acid or solid salts of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosage forms containing thioctic acid or solid salts of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage forms containing thioctic acid or solid salts of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2973912